Funded project
ExcepGen Inc - RNA therapeutics for longevity

ExcepGen Inc - RNA therapeutics for longevity

ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.
$ 100,000
80.66% Voted Yes
ExcepGen Website
Thomas Folliard
Barbara Mertins
Katherine Barcay

Seed stage start-up

Vaccines and RNA therapeutics


Patent Status
Portfolio of patent applications submitted



Severe viral infections can induce immune dysfunction and chronic inflammation, mimicking the symptoms of aging and often persisting even after the pathogen has been cleared. The NIH's National Institute on Aging emphasizes the serious threat that viruses, like influenza and COVID-19, pose to elderly adults. To combat these health risks, ExcepGen's RNAx platform focuses on enhancing the effectiveness of RNA cargo, thereby promoting the production of protective proteins within the body. Their primary project is the development of a universal pan-flu vaccine, utilizing the strengths of self-amplifying RNA (saRNA), while mitigating its inflammatory side effects, a breakthrough with significant potential in enhancing longevity.

Aims, Hypothesis & Results

ExcepGen's primary objective is to exploit the potential of its RNAx platform to develop an advanced generation of vaccines. The central aim is to construct a universal pan-flu vaccine that harnesses the advantages of self-amplifying RNA (saRNA) while minimizing the associated inflammatory drawbacks.

ExcepGen hypothesizes that by using RNAx to modulate signals within cells, it can enhance the effectiveness of RNA cargo. This process is expected to result in increased protein production and subsequently greater protection against severe viral infections, offering hope for aging populations.

Preliminary studies have shown promising results. Experiments using saRNAx produced a 400% boost in cargo expression in vivo in mice, compared to standard saRNA. In innate-immune-competent human BJ cells, saRNAx resulted in up to, 2600% improvement in cargo expression. Furthermore, saRNAx majorly reduced and, in some cases, completely prevented harmful inflammatory cytokine release, supporting the hypothesis of the project. Based on these encouraging results, ExcepGen is proceeding with the development of a universal pan-flu vaccine, among other pipeline products.


Currently, ExcepGen Inc is actively engaged in pre-clinical studies aimed at demonstrating the proof of concept (PoC) for a combination of universal influenza vaccine (Vx) and self-amplifying RNA (saRNA) in an animal model.

Pre-Clinical Studies
Required Funding: $100,000
Duration: Ongoing

VitaDAO Board Evaluation Writeup

ExcepGen's project received positive feedback and was praised for its advanced state, ample data, strong partnerships, and significant funding. The reviewers recommended funding, acknowledging the platform's potential for various therapeutic and prophylactic applications. They recognized the strong connection between flu vaccines and VitaDAO's mission, given the impact of flu on elderly populations. ExcepGen's technology's applicability to mRNA vaccines and potential for partnerships were noted, as was the strength of the team and investors.

Projects supported
No items found.

Latest Project Updates

Funding committed as a result of a strategic partnership between pharma and DeSci

The vote has passed, the decision is made: ExceptGen will be the first company sourced by VitaDAO’s strategic partner Pfizer Ventures to be funded by DeSci. This historic moment needs to be celebrated properly!

Project Initiated!

Discover more projects & initiatives

The Longevity Prize


The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.

$ 24,000
View Project

The VitaDAO Longevity Fellowship


The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.

$ 20,000
View Project

Humanity - Proprietary Aging Score App


Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
View Project

Matrix Bio - Long-lived Species Inspired Longevity Biotech


VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rats to humans.

$ 300,000
View Project

Are you working on the next longevity science breakthrough?

Click here to explore the VitaDAO Project Funding FAQ.